Antiangiogenic Therapy with Somatostatin Receptor-Mediated In Situ Radiation

Gulec, Seza A.; Gaffga, Christopher M.; O'Leary, J. Patrick; Anthony, Catherine T.; Su, L. Joseph; Woltering, Eugene A.
November 2001
American Surgeon;Nov2001, Vol. 67 Issue 11, p1068
Academic Journal
Tumor growth and the development of metastases require an angiogenic response. Angiogenic vessels uniquely express somatostatin subtype 2 (sst 2) receptors that can transport somatostatin or its analogs into the cell. We hypothesized that radiolabeled somatostatin analogs could inhibit the angiogenic response by selectively destroying proliferating endothelial cells. We evaluated the antiangiogenic effects of [sup 111]In-pentetreotide, an sst 2-preferring somatostatin analog in a human vessel model. Disks of human placental vein were embedded in fibrin gels in culture and observed for angiogenic sprouting for 14 days. Vein disks were treated with [sup 111]In-pentetreotide (1.5, 15, and 150 micro Ci/mL) on the day of implantation. Control groups included disks treated with nutrient medium alone, with [sup 111]In-chloride, and with unlabeled pentetreotide. The percentage of wells that initiated an angiogenic response and the overall length and density of neovessel sprouts were assessed on Day 14. [sup 111]In-pentetreotide treatment did not completely block initiation of the angiogenic response but significantly decreased the growth of neovessels after initiation. Both the receptor-specific Auger electron-induced and nonspecific gamma radiation-mediated effects contributed to the angiotoxicity.


Related Articles

  • The Hemostatic System and Angiogenesis in Malignancy. Wojtukiewicz, Marek Z; Sierko, Ewa; Klement, Petr; Rak, Janusz // Neoplasia;Sep2001, Vol. 3 Issue 5, p371 

    Coagulopathy and angiogenesis are among the most consistent host responses associated with cancer. These two respective processes, hitherto viewed as distinct, may in fact be functionally inseparable as blood coagulation and fibrinolysis, in their own right, influence tumor angiogenesis and...

  • Antiangiogenesis in Neurofibromatosis 1. Kurtz, Andreas; Martuza, Robert L. // Journal of Child Neurology;Aug2002, Vol. 17 Issue 8, p578 

    Antiangiogenesis therapy has become a potentially promising tool to inhibit tumor growth by targeting an essential yet untransformed tissue component. Identifying the factors involved and understanding the mechanisms required for tumor angiogenesis will facilitate efficient and specific...

  • A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Hori, K.; Saito, S.; Kubota, K. // British Journal of Cancer;5/20/2002, Vol. 86 Issue 10, p1604 

    In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumours, to demonstrate that a novel water-soluble combretastatin A-4 derivative, AC7700, abruptly and irreversibly stopped tumour blood flow. As a...

  • Thrombospondins as Anti-Angiogenic Therapeutic Agents. Vailhe, Bruno; Feige, Jean-Jacques // Current Pharmaceutical Design;Mar2003, Vol. 9 Issue 7, p583 

    Thrombospondin-1 (TSP-1) was one of the first endogenous inhibitors of angiogenesis to be discovered. This large multimodular protein of around 600 kDa inhibits endothelial cell proliferation, migration and morphogenic organization into capillary tubes. TSP-2 shares homology with TSP-1 in...

  • Heparin Derivatives as Angiogenesis Inhibitors. Presta, M.; Leali, D.; Stabile, H.; Ronca, R.; Camozzi, M.; Coco, L.; Moroni, E.; Liekens, S.; Rusnati, M. // Current Pharmaceutical Design;Mar2003, Vol. 9 Issue 7, p553 

    Angiogenesis is the process of generating new capillary blood vessels. Uncontrolled endothelial cell proliferation is observed in tumor neovascularization and in angioproliferative diseases. Tumors cannot growth as a mass above few mm3 unless a new blood supply is induced. It derives that the...

  • Applied vascular biology: can angiogenesis inhibitors help control malignant growth? Cramer, David A.; Cramer, D A // Annals of Internal Medicine;11/15/98, Vol. 129 Issue 10, p841 

    Focuses on the possible role of angiogenesis inhibitors in controlling the growth of malignant cancer. Ability of growth factors to regulate vessel growth and alter early neoplasm growth; Inhibition of matrix metalloproteinases; Ability of antiangiogenesis agents to attack tumor cells without...

  • Clinical trials to begin on potent angiogenesis inhibitors. Abbasi, Kamran // BMJ: British Medical Journal (International Edition);05/09/98, Vol. 316 Issue 7142, p1407 

    Reports on the clinical trials of two potent angiogenesis inhibitor drugs that are set to begin in the United States (US) in 1999. Research on endostatin and angiostatin; Tests for the drugs' mechanisms of action; Statement from the National Cancer Institute.

  • Development of lentiviral vectors for antiangiogenic gene delivery. Shichinohe, Toshiaki; Bochner, Bernard H; Mizutani, Kazuo; Nishida, Miyako; Hegerich-Gilliam, Susan; Naldini, Luigi; Kasahara, Noriyuki // Cancer Gene Therapy;Nov2001, Vol. 8 Issue 11, p879 

    Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their...

  • Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Jin, Xiaomei; Bookstein, Rob; Wills, Ken; Avanzini, Jenny; Tsai, Van; LaFace, Drake; Terracina, Gaby; Shi, Bin; Nielsen, Loretta L // Cancer Gene Therapy;Dec2001, Vol. 8 Issue 12, p982 

    Progressive growth and metastasis of solid tumors require angiogenesis, or the formation of new blood vessels. Endostatin is a 20-kDa carboxy-terminal fragment of collagen XVIII that has been shown to inhibit endothelial cell proliferation and tumor angiogenesis. Replication-deficient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics